MARKET

SRNE

SRNE

Sorrento Therapeutics Inc
NASDAQ
1.010
+0.050
+5.21%
After Hours: 1.030 +0.02 +1.98% 19:59 01/27 EST
OPEN
0.9620
PREV CLOSE
0.9600
HIGH
1.060
LOW
0.9620
VOLUME
17.14M
TURNOVER
0
52 WEEK HIGH
3.600
52 WEEK LOW
0.7360
MARKET CAP
476.60M
P/E (TTM)
-0.7595
1D
5D
1M
3M
1Y
5Y
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About
Benzinga · 3d ago
A SPAC, Spinoff, And Short Squeeze Walk Into A Bar
Seeking Alpha · 5d ago
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 5d ago
3M, Magna International And Other Big Stocks Moving Lower On Tuesday
Benzinga · 5d ago
Sorrento Therapeutics down 9% following phase 1 data on COVID-19 antiviral Ovydso
Seeking Alpha · 01/09 17:46
BRIEF-Sorrento Releases Positive Results From A Phase 1B Study In China In Covid-19 Patients And Is Ready For Pivotal Phase 3 Trials With Ovydso™ (Sti-1558), An Oral Mpro Inhibitor As A Standalone Treatment For Covid-19 Without The Need For Ritonavir Boosting
Reuters · 01/09 14:03
Sorrento Releases unblinded Phase 1b Study Data Of OVYDSO In COVID Patients
Benzinga · 01/09 14:00
Sorrento Therapeutics Says Ovydso Well Tolerated in Phase 1b COVID-19 China Trial
Sorrento Therapeutics Says Ovydso Well Tolerated in Phase 1b COVID-19 China Trial
MT Newswires · 01/09 12:40
More
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.